Diabetes Mellitus, Type 1
Conditions
Keywords
Diabetes Mellitus, Type 1, self-monitoring blood glucose, diabetes mobile application, diabetes management device
Brief summary
A more convenient blood glucose monitoring system integrated with a responsive mobile health app may facilitate improved diabetes control in adolescent and young adult patients with Type 1 diabetes. The primary aim of this study is to determine if the POPS diabetes management system can improve diabetes control in the adolescent and young adult population. The investigators hypothesize that use of the POPS diabetes management device and mobile application (app) will be associated with lower HbA1C after 6-months of use in adolescent and young adult T1D patients.
Detailed description
This is a prospective, single-arm, single-subject clinical trial to study outcomes related to device use in the pediatric diabetes population. Patients will be recruited at the Children's Minnesota McNeely Diabetes Clinic and satellite clinics during routine office visits over a 6-month period until recruitment goals are met. Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months with periodic check-ins and follow-ups. Primary outcome, HbA1c, will be measured at baseline and 6-month follow-up. Secondary aims include assessment of blood glucose testing frequency and quality of life scores following 6-months of device and app use. The investigators will also describe sustained use over the study period, average blood glucose and variability, and frequency of hypoglycemic events (blood glucose \<70). Historical data for each patient will also be recorded from medical records, with each patient serving as their own comparative control.
Interventions
DEVICEPops! One personalized mobile platform
Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
Sponsors
Pops! Diabetes Care
Children's Hospitals and Clinics of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
prospective, single-arm, single-subject clinical trial
Eligibility
Sex/Gender
ALL
Age
10 Years to 25 Years
Healthy volunteers
No
Inclusion criteria
1. Type 1 diabetes, diagnosed at least 6 months prior to enrollment 2. Aged ≥10 years, ≤25 years 3. Daily insulin of any type, administered as multiple daily injections (MDI) for at least 90 days prior to enrollment 4. Latest HbA1c ≥8.0%, ≤10.5% 5. Average self-blood glucose measurement frequency ≥2 per day and ≤4.5 per day based on meter download spanning 28-day period prior to qualifying HbA1c measurement 6. User of iPhone 5 or above with iOS above 10.0 7. English-speaking 8. Patient must be willing to only use POPS device to check blood glucose for duration of study (except in case of technical failure or emergency)
Exclusion criteria
1. Continuous glucose monitor user at time of enrollment or considering CGM use in the next 6 months 2. Concurrent participation in another study that may influence results 3. On insulin pump at time of recruitment or considering pump use in the next 6 months 4. Inability to perform self-care behaviors due to co-morbidities such as mental health disorder, developmental delay, or other prohibitive physical condition (blindness, etc) 5. Participation in a diabetes clinical trial intervention in the 12 months prior to enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c | 6 months | Change in HbA1c from baseline to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Testing frequency | 30 days prior to enrollment to 6 months post-enrollment | Blood glucose testing frequency |
| quality of life | 30 days prior to enrollment to 6 months post-enrollment | Peds QL diabetes module |
| Average blood glucose | 30 days prior to enrollment to 6 months post-enrollment | Average blood glucose during 30 days prior to enrollment and during the 6 month intervention |
| Blood glucose variability | 30 days prior to enrollment to 6 months post-enrollment | Blood glucose variability during 30 during prior to enrollment and during the 6 months of intervention |
| Hypoglycemia | 6 months | Frequency of hypoglycemic events during intervention |
Countries
United States
Contacts
Primary ContactLaura Gandrud, MD
Backup ContactKrista Mullen, BS
Outcome results
None listed